LOGIN  |  REGISTER
Assertio
C4 Therapeutics

Waystar to Speak at Upcoming Investor Conferences

November 26, 2024 | Last Trade: US$37.64 0.25 -0.66

LEHI, Utah and LOUISVILLE, Ky., Nov. 26, 2024 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today announced that Chief Executive Officer Matt Hawkins will speak at two upcoming investor conferences:

  • Evercore ISI HealthCONx Conference on Wednesday, December 4, 2024, at 1:20 p.m. Eastern Time.
  • Barclays 22nd Annual Global Technology Conference on Thursday, December 12, 2024, at 11:00 a.m. Pacific Time.

Waystar will provide live webcasts of both events on its Investor Relations website at https://investors.waystar.com/news-events/events. Recordings will also be available on the site after the events.

About Waystar

Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 18 of 22 institutions on the U.S. News Best Hospitals list. Waystar's enterprise-grade platform annually processes over 5 billion healthcare payment transactions, including over $1.2 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.

Investor Contact
Sandy Draper
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Kristin Lee
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Viking Therapeutics

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page